Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 12/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.39 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6348612 | 0.88 | MAPK14 (1.00) | MAPK14SMN1; SMN2RAB9ABRD4KAT2B | |
| SCHEMBL6371398 | 0.84 | MAPK14 (0.73) | MAPK14SMN1; SMN2RAB9AKDM4EMAPT | |
| SCHEMBL6232218 | 0.81 | MAPK14 (0.71) | MAPK14SMN1; SMN2RAB9ABRD4KAT2B | |
| SCHEMBL6370976 | 0.81 | MAPK14 (0.78) | MAPK14SMN1; SMN2RAB9AMAPTBRD4 | |
| SCHEMBL6371718 | 0.81 | MAPK14 (0.81) | MAPK14SMN1; SMN2RAB9APKMBRD4 | |
| SCHEMBL6376389 | 0.79 | MAPK14 (0.68) | MAPK14SMN1; SMN2RAB9AMAPTLMNA | |
| SCHEMBL6370469 | 0.79 | MAPK14 (0.67) | MAPK14SMN1; SMN2RAB9AMAPTLMNA | |
| SCHEMBL6231964 | 0.79 | MAPK14 (0.67) | MAPK14SMN1; SMN2RAB9ALMNABRD4 | |
| SCHEMBL6376415 | 0.78 | MAPK14 (1.00) | MAPK14SMN1; SMN2RAB9ABRD4KAT2B | |
| SCHEMBL6370767 | 0.77 | MAPK14 (0.72) | MAPK14SMN1; SMN2RAB9AMAPTBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256122-A1 | Substituted pyridazinones | PHARMACIA CORPORATION | 2005-11-17 | — | — | US | claimed |
| US-20050020594-A1 | Substituted pyridazinones | PHARMACIA CORPORATION | 2005-01-27 | — | — | US | claimed |
| US-20040142932-A1 | Substituted pyridazinones | PHARMACIA CORPORATION | 2004-07-22 | — | — | US | claimed |
| US-20050256122-A1 | Substituted pyridazinones | PHARMACIA CORPORATION | 2005-11-17 | — | — | US | disclosed |
| US-20050020594-A1 | Substituted pyridazinones | PHARMACIA CORPORATION | 2005-01-27 | — | — | US | disclosed |
| US-20040142932-A1 | Substituted pyridazinones | PHARMACIA CORPORATION | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142932-A1 | Substituted pyridazinones | MAP4K2, MAPK6, MAP3K6 | MAPK14 29/4885SMN1; SMN2 1185/4885RAB9A 2668/4885 |
| US-20050020594-A1 | Substituted pyridazinones | MAP4K2, MAPK6, MAP3K6 | MAPK14 34/4885SMN1; SMN2 1153/4885RAB9A 2627/4885 |
| US-20050256122-A1 | Substituted pyridazinones | MAP4K2, MAPK6, MAP3K6 | MAPK14 34/4885SMN1; SMN2 1153/4885RAB9A 2627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.